RespireRx Pharmaceuticals Inc

Change company Symbol lookup

Select an option...

RSPI RespireRx Pharmaceuticals Inc

MSEX Middlesex Water Co

EQIX Equinix Inc

PEAK Healthpeak Properties Inc

TAL TAL Education Group

CPLP Capital Product Partners LP

ONFO Onfolio Holdings Inc

CALB California BanCorp

LI Li Auto Inc

TASK Taskus Inc

Go

RespireRx Pharmaceuticals Inc. is engaged in the discovery and development of medicines for the treatment of psychiatric and neurological disorders. The Company is developing treatment options that address obstructive sleep apnea (OSA), attention deficit hyperactivity disorder (ADHD) epilepsy, chronic pain, including inflammatory and neuropathic pain, and recovery from spinal cord injury (SCI), which are conditions that affect people. It is developing a pipeline of new and re-purposed drug products based on its patent portfolios for two drug platforms: pharmaceutical cannabinoids platform, is developing compounds that target the body’s endocannabinoid system, and in particular, the re-purposing of dronabinol, an endocannabinoid CB1 and CB2 receptor agonist, for the treatment of obstructive sleep apnea (OSA) and neuromodulators platform includes AMPAkines that are positive allosteric modulators (PAMs) of AMPA-type glutamate receptors and GABAkines that are PAMs of GABAA receptors.